According to a new report Global Filgrastim Market, published by KBV research, The Global Filgrastim Market size is expected to reach $953.4 million by 2027, rising at a market growth of 8.0% CAGR during the forecast period.
The continuing biosimilars research along with the strong pipeline drugs is estimated to fuel the growth of the drug type segment over the forecast period.
The chemotherapy-induced neutropenia segment is projected to display the highest growth rate during the forecast period. It is owing to the attached side effects with life-threatening infections. Along with that, it can change the schedule for chemotherapy and affect the early and long-term results.
The Asia Pacific is anticipated to display the fastest growth rate over the forecast period. This growth is attributed to the rise in the number of cancer patients, particularly in emerging nations like China and India.
The North America market dominated the Global Filgrastim Market by Region in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $369.6 million by 2027. The Europe market is exhibiting a CAGR of 7.6% during (2021 - 2027). Additionally, The Asia Pacific market is estimated to grow at a CAGR of 9.4% during (2021 - 2027).
Full Report: https://www.kbvresearch.com/filgrastim-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksöz Group
By Drug Type
By Indication
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
